RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Forcing Bioasis to Answer"And before anyone highlights to me the benefits we are receiving as a Biodexa shareholder, yeah, it is not lost on me that we will be getting Midatech assets."
I think you really do have to look at the upside of the deal to make sense of the deal. There are two companies with shareholders unfamiliar with each companies assets and that can lead to serious problems. The dilution is easy to understand and can be seen in seconds. Many have talked about it. Appreciating the assets of each company can take serious effort and how many retail holders have put in a serious effort to this date? I don't see much effort here. One billion shares but 10's of billions in potential upside may be the case. Early stage assets are very difficult to value however. You have to rely on faith in leadership. That's why diversification is a must.
"This whole concept of combing two wrongs to make a right seems rather clown world to me."
25% of biotech companies were trading below cash in recent months. Consolidation is an adaptive response in this environment and normal. It's survival. We've been in a historic bear market.
"Furthermore, I am a Biosis investor because I was enamored with XB3 and the hope of getting drugs elegantly across the BBB to treat serious and debilitating CNS diseases."
Midatech's lead drug is for glioblastoma. BTI's own news release targeted glioblastoma for xB3. Glioblastoma is a natural for xB3. BTI has also developed xB3-Avastin for glioblastoma and other cancer applications for brain cancer. Midatech is brain cancer company.
BTI news release emphasizing glioblastoma for xB3:
"It's also essential to recognize one of the main receptors Transcend utilizes to trick the brain into opening the BBB is expressed in important regions of the brain, including areas critical to learning, memory, mood and impulsivity. This receptor is significantly expressed in glioblastomas and in key areas of the brain involved in a plethora of psychiatric and neurological diseases. I think these represent very intriguing targets for biOasis." June 2017